

GLOBAL BIOCHIP MARKETS: MICROARRAYS AND LAB-ON-A-CHIP



BIO049E
October 2013

John Bergin
Project Analyst

ISBN: 1-56965-604-5

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports:
carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
CONTRIBUTION OF THE STUDY AND FOR WHOM	2
SCOPE AND FORMAT	3
METHODOLOGY	3
INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	4
RELATED BCC REPORTS	4
BCC RESEARCH ONLINE SERVICES	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE GLOBAL VALUE OF BIOCHIP PRODUCTS BY END USE, THROUGH 2018 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL VALUE OF BIOCHIP PRODUCTS BY END USE, 2012-2018 (\$ MILLIONS)</i>	7
CHAPTER 3 OVERVIEW	10
INTRODUCTION	10
<i>TABLE 1 BIOLOGY DOWNSIZING REVOLUTION</i>	11
BIOCHIP TYPES	11
<i>TABLE 2 COMPARISON OF THE TWO MAJOR BIOCHIP TYPES</i>	12
<i>TABLE 3 BIOCHIP NOMENCLATURE</i>	13
SCOPE OF REPORT	14
<i>TABLE 4 SCOPE OF REPORT</i>	14
MARKET POTENTIAL OF BIOCHIPS	14
<i>TABLE 5 GLOBAL VALUE OF BIOCHIP PRODUCTS BY BIOCHIP TYPE, THROUGH 2018 (\$ MILLIONS)</i>	15
<i>TABLE 6 GLOBAL VALUE OF BIOCHIPS BY ANALYSIS FUNCTION, THROUGH 2018 (\$ MILLIONS)</i>	16
DRIVING FORCES FOR GROWTH IN BIOCHIPS MARKETS	17
<i>TABLE 7 BIOCHIPS KEY MARKET GROWTH DRIVING FORCES</i>	17
THE BIOCHIP INDUSTRY	18
<i>TABLE 8 COMPARISON OF BIOCHIPS INDUSTRIES</i>	18
CHAPTER 4 MICROARRAY TECHNOLOGIES	21
INTRODUCTION	21
<i>TABLE 9 THE NANOSCALE WORLD</i>	21
<i>TABLE 10 MICROARRAY TYPES</i>	22
<i>TABLE 11 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES</i>	22
DNA MICROARRAY TECHNOLOGIES	24
DNA MICROARRAY TYPES	24
<i>FIGURE 1 MICROARRAY FEATURE DENSITY</i>	24
<i>FIGURE 2 MICROARRAY RESOLUTION</i>	24
<i>TABLE 12 MICROARRAY GENOME CONTENT</i>	25

TOPIC	PAGE NO.
<i>TABLE 13 DNA MICROARRAY PLATFORM FEATURES</i>	26
DNA MICROARRAY APPLICATIONS	27
<i>TABLE 14 DNA MICROARRAY APPLICATIONS</i>	27
<i>TABLE 15 GENETIC ANALYSIS TECHNOLOGIES COMPARISON</i>	28
<i>FIGURE 3 RELATIVE NUMBER OF DISEASE-CAUSING ALLELES AT MAF5 AND MAF1</i>	29
SNP ANALYSIS	30
<i>TABLE 16 SNP MEASUREMENT PLATFORMS</i>	31
EPIGENETIC ANALYSIS	31
<i>FIGURE 4 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS</i>	32
CYTOGENETIC ANALYSIS	33
<i>TABLE 17 COMPARISON OF CHROMOSOMAL CHANGE DETECTION TECHNOLOGIES</i>	34
MICRO-RNA ANALYSIS	35
<i>TABLE 18 WORKFLOW FOR A MICRO-RNA EXPERIMENT</i>	36
BEAD-BASED ARRAYS	37
<i>TABLE 19 BEAD-BASED ARRAYS VERSUS PLANAR MICROARRAYS</i>	37
CATALOG AND CUSTOM DNA MICROARRAYS	37
PROTEIN MICROARRAY TECHNOLOGIES	37
INTRODUCTION	37
<i>FIGURE 5 IMPORTANCE OF PROTEINS</i>	38
PROTEOMICS WORKFLOW	38
<i>FIGURE 6 PROTEIN ANALYSIS APPROACHES CONTRASTED</i>	39
PROTEIN MICROARRAY DESIGN FEATURES	40
<i>TABLE 20 PROTEIN MICROARRAY PLATFORMS</i>	40
PROTEIN MICROARRAY APPLICATIONS AS RESEARCH TOOLS	41
<i>TABLE 21 PROTEIN MICROARRAYS AS RESEARCH TOOLS</i>	41
PROTEIN MICROARRAY TYPES	42
<i>TABLE 22 PROTEIN MICROARRAY PRODUCT TYPES</i>	42
PROTEIN MICROARRAY TECHNOLOGY CHALLENGES	44
<i>TABLE 23 PROTEIN MICROARRAY TECHNICAL CHALLENGES</i>	44
EMERGING MICROARRAY TECHNOLOGIES	47
<i>TABLE 24 EMERGING MICROARRAY TECHNOLOGIES</i>	47
GLYCOMICS MICROARRAYS	47
TISSUE MICROARRAYS	48
CHAPTER 5 LAB-ON-A-CHIP TECHNOLOGIES	51
INTRODUCTION	51
<i>TABLE 25 LOAC PRODUCT LIFE CYCLE STAGE</i>	51
SUBSTRATE MATERIALS	52
<i>TABLE 26 BIOCHIPS SUBSTRATE MATERIALS</i>	52
LOAC TYPES	53
<i>TABLE 27 LOAC TYPES</i>	53
IN VITRO PROTEOMICS	54
ELECTROPHORESIS ON A CHIP	54
STRUCTURAL PROTEOMICS	54
PCR ON A CHIP	55
IMMUNOASSAY ON A CHIP	56
MASS SPECTROMETRY ON CHIP	57

TOPIC	PAGE NO.
NEXT-GENERATION SEQUENCING ON CHIP	57
<i>TABLE 28 WORKFLOW COMPARISON OF SELECTED NEXT-GENERATION DNA SEQUENCING PLATFORMS</i>	58
<i>TABLE 29 BIOCHIP CONTENT IN NEXT-GENERATION SEQUENCING MACHINES</i>	58
LOAC APPLICATIONS	60
<i>TABLE 30 LOAC MARKET SEGMENTS</i>	60
<i>TABLE 31 MICROFLUIDIC SYSTEMS ADVANTAGES FOR BIOCHEMICAL ANALYSIS</i>	61
ORGAN ON CHIP	61
LOAC TECHNOLOGY CHALLENGES	62
<i>TABLE 32 LOAC TECHNOLOGY CHALLENGES</i>	62
CHAPTER 6 DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS	65
INTRODUCTION	65
<i>TABLE 33 BIOCHIP KEY LIFE-SCIENCES MARKET SEGMENTS</i>	65
DRUG INDUSTRY CHALLENGES	66
DRUG DISCOVERY AND DEVELOPMENT PROCESS	67
<i>FIGURE 7 DRUG DISCOVERY AND DEVELOPMENT TIMESCALE</i>	67
<i>TABLE 34 BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT</i>	68
DRUG TARGET IDENTIFICATION	69
DRUG DISCOVERY	70
Structural Biology	70
Lead Generation	70
Lead Optimization	73
Process R&D	73
Preclinical and Clinical Trials	74
NEEDS IN THE DRUG DISCOVERY AND DEVELOPMENT PROCESS	74
<i>TABLE 35 KEY NEEDS IN DRUG DISCOVERY AND DEVELOPMENT</i>	74
<i>FIGURE 8 VALIDATION GAP FOR FUTURE DRUG TARGETS</i>	76
CHAPTER 7 DIAGNOSTICS APPLICATIONS	79
INTRODUCTION	79
<i>TABLE 36 DIAGNOSTICS PARADIGM SHIFT</i>	79
HOW DIAGNOSTICS DIFFER FROM RESEARCH TOOLS	80
<i>TABLE 37 REQUIREMENTS FOR AN EPIGENETICS BISULFITE DIAGNOSTIC ASSAY</i>	80
HOW BIOLOGICAL CONTENT DRIVES THE GROWTH OF DIAGNOSTICS	81
<i>TABLE 38 BIOMARKERS USED IN BIOCHIP-BASED DIAGNOSTICS</i>	81
FACTORS IN CLINICAL ACCEPTANCE OF BIOMARKER-BASED TESTS	83
<i>TABLE 39 RATE OF ADOPTION OF DNA MICROARRAY DIAGNOSTICS TESTS</i>	83
MOLECULAR DIAGNOSTICS	84
INTRODUCTION	84
MARKET CHALLENGES FOR DNA-BASED MDX PLATFORMS	85
<i>TABLE 40 COMPARISON OF DNA-BASED MDX PLATFORMS</i>	86
<i>TABLE 41 FACTORS AFFECTING PENETRATION OF NEXT-GENERATION FORMATS INTO THE MDX MARKET</i>	87
DIAGNOSTICS MARKET SEGMENTS	88
TEST SENSITIVITY AND SPECIFICITY	89
<i>FIGURE 9 SENSITIVITY AND SPECIFICITY</i>	90
REGULATORY STATUS	91

TOPIC	PAGE NO.
BIOCHIPS CANCER APPLICATIONS	91
CANCER OVERVIEW	91
<i>TABLE 42 ESTIMATED U.S. INCIDENCE FOR SELECTED CANCERS, 2012</i>	92
BLADDER CANCER	93
<i>TABLE 43 STATUS OF ADVANCED BLADDER CANCER DIAGNOSTICS</i>	93
BREAST CANCER	95
Breast Cancer Screening	95
Prognosis and Pharmacogenetics Tests	95
<i>TABLE 44 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT DECISIONS IN THE U.S. BY CANCER CLASSIFICATION</i>	96
Breast Cancer MDx Platforms	97
<i>TABLE 45 BREAST CANCER MDX TECHNOLOGY PLATFORMS</i>	97
<i>TABLE 46 STATUS OF ADVANCED BREAST CANCER DIAGNOSTICS</i>	98
CERVICAL CANCER	102
<i>TABLE 47 STATUS OF ADVANCED HPV DIAGNOSTICS</i>	104
COLORECTAL CANCER	106
Conventional Colorectal Cancer Screening Tests	107
<i>TABLE 48 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL CANCER</i>	107
Molecular Colorectal Cancer Diagnostics Tests	108
<i>TABLE 49 STATUS OF ADVANCED COLORECTAL CANCER DIAGNOSTICS</i>	108
CANCER OF UNKNOWN PRIMARY (CUP)	110
<i>TABLE 50 CANCER UNKNOWN PRIMARY INDUSTRY</i>	111
KIDNEY CANCER	113
<i>TABLE 51 STATUS OF ADVANCED KIDNEY CANCER DIAGNOSTICS</i>	113
LEUKEMIA	114
<i>TABLE 52 STATUS OF ADVANCED LEUKEMIA DIAGNOSTICS</i>	114
LIVER CANCER	116
<i>TABLE 53 STATUS OF LIVER CANCER NEXT-GENERATION DX TESTS</i>	117
LYMPHOMA	118
<i>TABLE 54 STATUS OF ADVANCED LYMPHOMA CANCER DIAGNOSTICS</i>	118
LUNG CANCER	119
<i>TABLE 55 FIVE-YEAR SURVIVAL RATES FOR NON SMALL CELL LUNG CANCER (%)</i>	119
<i>TABLE 56 STATUS OF ADVANCED LUNG CANCER DIAGNOSTICS</i>	120
MELANOMA	124
<i>TABLE 57 STATUS OF ADVANCED MELANOMA DIAGNOSTICS</i>	125
OVARIAN CANCER	126
<i>TABLE 58 EARLY SCREENING OVARIAN CANCER TESTS</i>	126
<i>TABLE 59 STATUS OF OVARIAN CANCER NEXT-GENERATION DIAGNOSTICS TESTS</i>	127
PANCREATIC CANCER	129
<i>TABLE 60 STATUS OF ADVANCED PANCREATIC CANCER DIAGNOSTICS</i>	129
PROSTATE CANCER	130
<i>TABLE 61 STATUS OF ADVANCED PROSTATE CANCER DIAGNOSTICS</i>	132
THYROID CANCER	135
<i>TABLE 62 STATUS OF ADVANCED THYROID CANCER DIAGNOSTICS</i>	135
SUMMARY OF ADVANCED CANCER DIAGNOSTICS	136
<i>TABLE 63 NEXT-GENERATION DX TEST SUMMARY BY INDICATION AND BY TECHNOLOGY</i>	136

TOPIC	PAGE NO.
WARFARIN SENSITIVITY	137
<i>TABLE 64 IMPORTANCE OF CYP GENES IN DRUG METABOLISM</i>	138
<i>TABLE 65 STATUS OF ADVANCED WARFARIN CYP PHARMACOGENETIC DIAGNOSTICS</i>	139
INFECTIOUS DISEASES	141
TUBERCULOSIS	141
HOSPITAL-ACQUIRED INFECTIONS	142
<i>TABLE 66 STATUS OF MRSA AND C. DIFFICILE ADVANCED DIAGNOSTICS</i>	142
INFLUENZA	143
<i>TABLE 67 STATUS OF INFLUENZA ADVANCED DIAGNOSTICS</i>	144
SEXUALLY TRANSMITTED DISEASES	145
<i>TABLE 68 STATUS OF CT/NG ADVANCED DIAGNOSTICS</i>	146
OTHER INFECTIOUS DISEASES	146
NEUROLOGICAL	147
ALZHEIMER'S DISEASE	147
<i>TABLE 69 ALZHEIMER'S DISEASE DIAGNOSTICS APPROACHES</i>	148
<i>TABLE 70 STATUS OF ALZHEIMER'S DISEASE ADVANCED DIAGNOSTICS TESTS</i>	148
SCHIZOPHRENIA	149
CARDIAC DISORDERS	150
CONGESTIVE HEART FAILURE	150
<i>TABLE 71 BNP MOLECULAR DIAGNOSTICS TESTS FOR CONGESTIVE HEART FAILURE</i>	151
CYSTIC FIBROSIS	152
<i>TABLE 72 CYSTIC FIBROSIS ADVANCED DIAGNOSTICS TESTS</i>	153
NONINVASIVE PRENATAL SCREENING	154
<i>TABLE 73 NEXT-GENERATION SEQUENCING-BASED PRENATAL DIAGNOSTICS INDUSTRY</i>	155
IMMUNE DISORDERS	156
HLA TYPING	156
<i>TABLE 74 HLA TESTING MARKET</i>	157
AUTOIMMUNE TESTING	158
CHAPTER 8 BIOCHIPS INDUSTRY	161
BIOCHIPS INDUSTRY ACQUISITIONS, 2012-2013	161
<i>TABLE 75 ACQUISITIONS IN THE BIOCHIPS INDUSTRY, 2012-2013</i>	161
BIOCHIPS INDUSTRY STRATEGIC ALLIANCES, 2012-2013	164
MICROARRAY INDUSTRY STRATEGIC ALLIANCES, 2012-2013	164
<i>TABLE 76 MICROARRAY INDUSTRY STRATEGIC ALLIANCES, 2012-2013</i>	165
LOAC INDUSTRY STRATEGIC ALLIANCES, 2012-2013	169
<i>TABLE 77 LOC/NGS INDUSTRY STRATEGIC ALLIANCES, 2012-2013</i>	169
LOAC INDUSTRY	177
LOAC INDUSTRY OVERVIEW	178
<i>TABLE 78 LOAC COMPETITOR LANDSCAPE</i>	178
LOAC INSTRUMENT INDUSTRY	179
<i>TABLE 79 LEADING LOAC INSTRUMENT MANUFACTURERS</i>	180
LOAC DNA ANALYZER INDUSTRY	181
<i>TABLE 80 FORENSIC APPLICATIONS FOR LOAC-BASED DNA ANALYZERS</i>	181
LOAC DIAGNOSTICS INDUSTRY	182
<i>TABLE 81 LOAC DIAGNOSTICS INDUSTRY</i>	182

TOPIC	PAGE NO.
ION CHANNEL SCREENING INDUSTRY	182
<i>TABLE 82 ION CHANNEL SCREENING INDUSTRY</i>	183
DIGITAL PCR INDUSTRY	183
<i>TABLE 83 DIGITAL PCR INDUSTRY</i>	184
INFLUENTIAL UNIVERSITIES IN THE LOAC INDUSTRY	185
<i>TABLE 84 LOC UNIVERSITY SPIN-OFFS</i>	185
ROLE OF LOAC ACQUISITIONS IN LIFE SCIENCES INDUSTRY	186
<i>TABLE 85 LEADING LIFE SCIENCE COMPANIES ACQUISITIONS IN LOAC</i>	186
NEXT-GENERATION SEQUENCING INSTRUMENT INDUSTRY	187
<i>TABLE 86 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES: COMMERCIAL PHASE</i>	187
MICROARRAY INDUSTRY	188
SUSPENSION BEAD/GEL-BASED MICROARRAY INDUSTRY	188
<i>TABLE 87 SUSPENSION BEAD/GEL-BASED MICROARRAY INDUSTRY</i>	188
LABEL-FREE DETECTION INDUSTRY	189
<i>TABLE 88 LABEL-FREE DETECTION INDUSTRY</i>	189
NANOARRAY INDUSTRY	191
<i>TABLE 89 NANOARRAY INDUSTRY</i>	191
PEPTIDE MICROARRAY INDUSTRY	191
<i>TABLE 90 KEY PEPTIDE MICROARRAY COMPANIES</i>	192
ANTIBODY MICROARRAY INDUSTRY	192
<i>TABLE 91 KEY ANTIBODY MICROARRAY COMPANIES</i>	193
ANTIBODY REAGENTS INDUSTRY	194
<i>TABLE 92 MARKET SHARE FOR KEY ANTIBODY REAGENTS COMPANIES</i>	194
BIOCHIPS DIAGNOSTICS INDUSTRY	195
MULTIPLEX PROTEIN DIAGNOSTICS INDUSTRY	195
<i>TABLE 93 MULTIPLEX PROTEIN IN VITRO DIAGNOSTICS COMPANIES</i>	195
CIRCULATING TUMOR CELL INDUSTRY	197
<i>TABLE 94 CTC BIOCHIPS INDUSTRY</i>	198
PRENATAL DIAGNOSTICS INDUSTRY	199
<i>TABLE 95 NORTH AMERICAN TEST COSTS AND PRICES (\$)</i>	200
<i>TABLE 96 NEXT-GENERATION SEQUENCING-BASED, NONINVASIVE PRENATAL DIAGNOSTIC MARKET SHARE BY TEST REVENUE, 2013 (%)</i>	201
<i>TABLE 97 NONINVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE COMPETITORS</i>	202
POC CD4 COUNTING INDUSTRY	202
<i>TABLE 98 POC CD4 INDUSTRY</i>	203
AGRICULTURAL INDUSTRY	203
<i>TABLE 99 BIOCHIPS-BASED COMPANIES IN AGRICULTURAL INDUSTRY</i>	204
CHINA'S BIOCHIP INDUSTRY	205
<i>TABLE 100 CHINA BIOCHIP INDUSTRY</i>	206
CHAPTER 9 BIOCHIPS MARKETS	210
DRIVING FORCES FOR BIOCHIPS GROWTH	210
<i>TABLE 101 BIOCHIPS KEY MARKET GROWTH DRIVING FORCES</i>	210
GLOBAL BIOCHIPS MARKET	211
<i>TABLE 102 GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, THROUGH 2018 (\$ MILLIONS)</i>	211

TOPIC	PAGE NO.
<i>TABLE 103 GLOBAL VALUE OF BIOCHIP MARKET BY END-USE INDUSTRY, THROUGH 2018 (\$ MILLIONS)</i>	212
<i>TABLE 104 BIOCHIPS SUBSTRATE MATERIALS</i>	213
<i>TABLE 105 GLOBAL VALUE OF BIOCHIP MARKET BY SUBSTRATE MATERIAL, THROUGH 2018 (\$ MILLIONS)</i>	213
DNA MICROARRAY MARKETS	214
DNA MICROARRAY MARKET BY END-USE INDUSTRY	214
<i>TABLE 106 GLOBAL VALUE OF DNA MICROARRAYS BY END USE, THROUGH 2018 (\$ MILLIONS)</i>	214
DNA MICROARRAY MARKET BY ANALYSIS TYPE	216
<i>TABLE 107 GLOBAL VALUE OF DNA MICROARRAYS BY ANALYSIS TYPE, THROUGH 2018 (\$ MILLIONS)</i>	216
<i>FIGURE 10 ENTRIES TO MIRNA DATABASE, 2002-2013 (NO. OF MIRNAS)</i>	218
DNA MICROARRAY MARKET BY SUBSTRATE MATERIAL	219
<i>TABLE 108 GLOBAL VALUE OF DNA MICROARRAYS BY SUBSTRATE MATERIAL, THROUGH 2018 (\$ MILLIONS)</i>	219
PROTEIN MICROARRAYS MARKETS	219
INTRODUCTION	219
<i>TABLE 109 COMPETITIVE PLATFORMS BY MULTIPLEXING DENSITY</i>	220
PROTEIN MICROARRAYS MARKET BY END-USE INDUSTRY	221
<i>TABLE 110 GLOBAL VALUE OF PROTEIN MICROARRAYS BY END USE, THROUGH 2018 (\$ MILLIONS)</i>	221
PROTEIN MICROARRAYS MARKET BY SUBSTRATE MATERIAL	222
<i>TABLE 111 GLOBAL VALUE OF PROTEOMIC MICROARRAYS BY SUBSTRATE MATERIAL, THROUGH 2018 (\$ MILLIONS)</i>	223
<i>TABLE 112 COATED MICROARRAY SLIDE MARKET PRINCIPAL COMPETITORS</i>	223
PROTEOMIC MICROARRAYS MARKET BY ARRAY TYPE	224
<i>TABLE 113 GLOBAL VALUE OF PROTEOMIC ARRAYS BY ARRAY TYPE, THROUGH 2018 (\$ MILLIONS)</i>	224
EMERGING MICROARRAYS MARKETS	225
EMERGING MICROARRAYS MARKET BY TECHNOLOGY	225
<i>TABLE 114 GLOBAL VALUE OF EMERGING ARRAYS, BY ARRAY TYPE, THROUGH 2018 (\$ MILLIONS)</i>	225
EMERGING MICROARRAYS MARKETS BY END-USE INDUSTRY	226
<i>TABLE 115 GLOBAL VALUE OF EMERGING ARRAYS BY END USE, THROUGH 2018 (\$ MILLIONS)</i>	226
EMERGING ARRAYS MARKET BY SUBSTRATE TYPE	227
<i>TABLE 116 GLOBAL VALUE OF EMERGING ARRAYS BY SUBSTRATE MATERIAL, THROUGH 2018 (\$ MILLIONS)</i>	227
LOAC MARKETS	227
GENOMICS LOAC MARKET BY END-USE INDUSTRY	227
<i>TABLE 117 GLOBAL VALUE OF GENOMICS LAB-ON-A-CHIP BY END-USER INDUSTRY, THROUGH 2018 (\$ MILLIONS)</i>	228
GENOMICS LOAC MARKET BY SUBSTRATE TYPE	229
<i>TABLE 118 GLOBAL VALUE OF GENOMICS LOAC BY SUBSTRATE MATERIAL, THROUGH 2018 (\$ MILLIONS)</i>	229
PROTEOMICS LOAC MARKET BY END-USE INDUSTRY	230
<i>TABLE 119 GLOBAL VALUE OF PROTEOMIC LAB-ON-A-CHIP BY END-USER INDUSTRY, THROUGH 2018 (\$ MILLIONS)</i>	230
PROTEOMICS LOAC MARKET BY SUBSTRATE TYPE	232

TOPIC	PAGE NO.
<i>TABLE 120 GLOBAL VALUE OF PROTEOMICS LOAC BY SUBSTRATE MATERIAL, THROUGH 2018</i>	232
NGS MARKETS	233
NGS MARKETS BY END-USER INDUSTRY	233
<i>TABLE 121 GLOBAL VALUE OF NGS MARKET BY END-USER INDUSTRY, THROUGH 2018 (\$ MILLIONS)</i>	233
NGS MARKET BY SUBSTRATE TYPE	234
<i>TABLE 122 GLOBAL VALUE OF NGS BY SUBSTRATE MATERIAL, THROUGH 2018 (\$ MILLIONS)</i>	234
NGS MARKETS BY TEST COMPLEXITY	235
<i>TABLE 123 GLOBAL VALUE OF NGS BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)</i>	235
BIOCHIPS DIAGNOSTICS MARKETS	237
INTRODUCTION	237
DIAGNOSTICS MARKET BY BIOCHIP TYPE	237
<i>TABLE 124 GLOBAL VALUE OF DIAGNOSTICS MARKET, BY BIOCHIP TYPE, THROUGH 2018 (\$ MILLIONS)</i>	238
<i>TABLE 125 ADOPTION RATE FOR DNA MICROARRAYS IN DIAGNOSTICS</i>	240
DIAGNOSTICS MARKET BY INDICATION	241
<i>TABLE 126 GLOBAL VALUE OF DIAGNOSTICS MARKET, BY INDICATION, THROUGH 2018 (\$ MILLIONS)</i>	241
DIAGNOSTICS MARKET BY SUBSTRATE MATERIAL	245
<i>TABLE 127 GLOBAL VALUE OF DIAGNOSTICS MARKET BY SUBSTRATE MATERIAL, THROUGH 2018 (\$ MILLIONS)</i>	246
CANCER DIAGNOSTICS MARKET BY BIOCHIP TYPE	246
<i>TABLE 128 GLOBAL VALUE OF CANCER DIAGNOSTICS MARKET BY BIOCHIP TYPE, THROUGH 2018 (\$ MILLIONS)</i>	247
CANCER DIAGNOSTICS MARKET BY INDICATION	248
<i>TABLE 129 GLOBAL VALUE OF CANCER DIAGNOSTICS MARKET BY INDICATION, THROUGH 2018 (\$ MILLIONS)</i>	248
<i>TABLE 130 2013 STATUS OF PROTEOMICS-BASED DIAGNOSTICS FOR CANCER APPLICATIONS</i>	249
BIOCHIPS GEOGRAPHIC MARKETS	251
GEOGRAPHY MARKET SUMMARY	251
<i>TABLE 131 GLOBAL VALUE OF BIOCHIPS MARKET BY GEOGRAPHY, THROUGH 2018 (\$ MILLIONS)</i>	251
MICROARRAY MARKET BY GEOGRAPHY	252
<i>TABLE 132 GLOBAL VALUE OF MICROARRAY MARKET BY GEOGRAPHY, THROUGH 2018 (\$ MILLIONS)</i>	253
LOAC MARKET BY GEOGRAPHY	254
<i>TABLE 133 GLOBAL VALUE OF LOAC MARKET BY GEOGRAPHY, THROUGH 2018 (\$ MILLIONS)</i>	254
NGS MARKET BY GEOGRAPHY	255
<i>TABLE 134 GLOBAL VALUE OF NGS MARKET BY GEOGRAPHY, THROUGH 2018 (\$ MILLIONS)</i>	255
CHAPTER 10 BIOCHIPS PATENTS	258
MICROARRAY PATENTS	258
<i>TABLE 135 DNA MICROARRAY PATENTS BY REGION, 2002-2012</i>	258
<i>TABLE 136 MICROARRAY-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012</i>	259

TOPIC	PAGE NO.
LOAC PATENTS	259
<i>TABLE 137 LOAC-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012</i>	260
CLINICAL NEXT-GENERATION SEQUENCING PATENTS	260
CLINICAL NGS PATENTS SUMMARY	260
<i>TABLE 138 CLINICAL NEXT-GENERATION SEQUENCING PATENTS, 2002-2012</i>	261
CLINICAL NGS PATENTS BY INDICATION	261
<i>TABLE 139 CLINICAL NEXT-GENERATION SEQUENCING PATENTS BY INDICATION, 2002-2012</i>	261
CHAPTER 11 COMPANY PROFILES	264
3QBD	264
20/20 GENE SYSTEMS, INC.	264
ABAXIS, INC.	265
ABBOTT LABORATORIES	266
ABIONIC SA	266
ABTECH SCIENTIFIC, INC.	267
ABACUS DIAGNOSTICA LTD.	267
ACCELERATE DIAGNOSTICS, INC.	268
ACEA BIOSCIENCES, INC.	268
ACHIRA LABS PVT. LTD.	268
ADVANCED LIQUID LOGIC	269
AFFYMETRIX, INC.	269
AGENDIA BV	271
<i>TABLE 140 AGENDIA MICROARRAY-BASED DIAGNOSTICS PIPELINE</i>	271
AGENIX LTD.	272
AGILENT TECHNOLOGIES, INC.	272
AKONNI BIOSYSTEMS	273
<i>TABLE 141 AKONNI BIOCHIP GRANTS</i>	274
ALERE TECHNOLOGIES GMBH	275
ALLEGRO DIAGNOSTICS CORP.	276
ALMAC GROUP, LTD.	277
ANAGNOSTICS BIOANALYSIS GMBH	277
ANALYTIK JENA AG	278
AQUAMARIJIN MICRO FILTRATION BV	279
AQUILA DIAGNOSTIC SYSTEMS INC.	279
ARCXIS BIOTECHNOLOGIES, INC.	279
ARRAYIT CORPORATION	280
ASSURERX HEALTH, INC.	281
ATONOMICS A/S	281
AUSHON BIOSYSTEMS, INC.	282
AUTOGENOMICS, INC.	282
AVACTA GROUP PLC	283
AVIANA MOLECULAR TECHNOLOGIES	283
AXELA, INC.	284
AYANDA BIOSYSTEMS SA	284
AYOXXA BIOSYSTEMS GMGH	285
BECKMAN COULTER, INC.	285
BECKMAN COULTER BIOMEDICAL GMBH	286

TOPIC	PAGE NO.
BECTON, DICKINSON AND CO.	286
BIOCARTIS SA	288
BIOCEPT, INC.	288
BIODOT, INC.	289
BIOFIRE DIAGNOSTICS, INC.	289
BIOFLUIDIX GMBH	290
BIOFORCE NANOSCIENCES, INC.	290
BIOMERIEUX SA	290
BIONANOGENOMICS, INC.	291
BIORAD LABORATORIES, INC.	292
BIOSCALE, INC.	293
BIOSURFIT, SA	293
BIOSYSTEMS INTERNATIONAL	294
BIOTRAY	294
BIOVITESSE, INC.	294
BLUE4GREEN	295
BODITECH MED, INC.	295
BOEHRINGER INGELHEIM MICROPARTS GMBH	295
BOSTON MICROFLUIDICS	296
CAMBRIDGE BIOMAGNETICS LTD.	296
CANCER GENETICS, INC.	296
CAPITALBIO CORPORATION	297
CARIS LIFE SCIENCES	298
CBC COMPREHENSIVE BIOMARKER CENTER GMBH	298
CELLANYX DIAGNOSTICS, INC.	298
CELLASIC	299
CELLECTRICON AB	299
CELLIX, LTD.	300
CELLSCAPE CORPORATION	300
CELLULA, INC.	300
CELLULAR RESEARCH, INC.	301
CEPHEID	301
CLEARBRIDGE BIOMEDICS	302
COMBIMATRIX MOLECULAR DIAGNOSTICS, INC.	303
COURTAGEN LIFE SCIENCES, INC.	303
CREATIVE MICROSYSTEMS CORPORATION	304
CUSTOMARRAY, INC.	304
CYBRDI, INC.	304
CYCLOFLUIDIC LTD.	305
CYNVENIO BIOSYSTEMS, INC.	305
CYTOCENTRICS BIOSCIENCE GMBH	306
CYTOO SA	306
DAKTARI DIAGNOSTICS, INC.	306
DEBIOTECH S.A.	307
DELTADOT LTD.	307
DEOS LABS	307
DIAGENIC ASA	308

TOPIC	PAGE NO.
DIAGNOSTICS FOR ALL	308
DIAGNOSWISS S.A.	309
DIAXONHIT	310
DIGITAL GENOMICS	310
DNA ELECTRONICS LTD.	311
DNA LINK, INC.	311
DNAMICROARRAY, INC.	312
DOLOMITE MICROFLUIDICS LTD.	312
DR. CHIP BIOTECH, INC.	313
DST DIAGNOSTISCHE SYSTEME & TECHNOLOGIEN GMBH	313
DYCONEX AG	314
EKSIGENT	314
ELIM BIOPHARMACEUTICALS, INC.	314
EPIGEM LTD.	315
EPOCAL, INC.	315
EUROIMMUN AG	315
ELEVFLOW	316
FALCON GENOMICS, INC.	316
FLUIDIGM CORPORATION	317
FLUIMEDIX APS	318
FLUIDWARE TECHNOLOGIES, INC.	318
FLUIMETRICS, INC.	319
FLUXION BIOSCIENCES, INC.	319
FLYION GMBH	319
FULL MOON BIOSYSTEMS, INC.	320
GEN9, INC.	320
GENALYTE	320
GENEFLUIDICS, INC.	321
GENENEWS	321
GENEPOC, INC.	321
GENMARK DIAGNOSTICS, INC.	322
GENOMEDX BIOSCIENCES, INC.	323
GENOMICA SAU	323
GIGAGEN, INC.	324
GNUBIO, INC.	324
GOOD START GENETICS, INC.	325
GRACE BIO LABS	326
GRADIENSTECH AB	326
GWC TECHNOLOGIES, INC.	326
GYROS AB	327
HNU-NANOPOINT	327
HOLOGIC, INC.	327
ILLUMINA, INC.	328
IMMUNOVIA AB	330
INNANOVATE, INC.	330
INNOSIEVE DIAGNOSTICS BV	331
INOSTICS GMBH	331

TOPIC	PAGE NO.
INSTITUTE OF MICROCHEMICAL TECHNOLOGY CO., LTD.	331
INTAVIS BIOANALYTICAL INSTRUMENTS AG	332
INTEGRATED PLASMONICS CORP.	332
INTEL CORPORATION	333
IQUUM, INC.	333
IRIS BIOTECHNOLOGIES, INC.	333
ISU ABXIS CO., LTD.	334
JOHNSON & JOHNSON	335
JPT PEPTIDE TECHNOLOGIES GMBH	335
KINEXUS BIOINFORMATICS CORPORATION	336
KUMETRIX, INC.	337
LAB21 HEALTHCARE LTD.	337
LABORATORY CORPORATION OF AMERICA, INC.	338
LC SCIENCES	338
LEUKODX LTD.	339
LIFE BIOSCIENCES, INC.	339
LIFE TECHNOLOGIES, INC.	340
LINEAGEN, INC.	342
LIONIX BV	342
LUMINEX	343
MAGARRAY, INC.	344
MAXWELL SENSORS INC.	344
MEDIMATE B.V.	345
MERCK KGAA	345
METAMARK GENETICS, INC.	346
MICROFLUIDIX, INC.	346
MICRO2GEN LTD.	346
MICROCHIPS, INC.	347
MICRODISH BV	347
MICRODROP TECHNOLOGIES GMBH	348
MICROFAB TECHNOLOGIES, INC.	348
MICROFLEXIS GMBH	348
MICROFLUIDIC CHIPSHOP GMBH	349
MICROFLUIDIC INNOVATIONS, LLC	349
MICROLIQUID	350
MICROLYTIC	350
MICRONICS, INC.	350
MICRONIT MICROFLUIDICS BV	351
MICROPOINT BIOSCIENCES, INC.	352
MICRUX TECHNOLOGIES SA	352
MINGYUAN MEDICARE DEVELOPMENT COMPANY, LTD.	352
MOBIDIAG OY/LTD.	353
MODE DX, LTD.	353
MOLECULAR CYTOMICS INC.	354
MOLECULAR VISION LTD	354
MYCROARRAY, INC.	355
MYCROLAB DIAGNOSTICS PTY LTD.	355

TOPIC	PAGE NO.
NANION TECHNOLOGIES GMBH	356
NANO TERRA, INC.	356
NANOBIOSYM	356
NANOBIOSYS	357
NANOCELLECT BIOMEDICAL INC.	357
NANOENTEK, INC.	358
NANOIVD, INC.	358
NANOLABWARE S.A.S.U.	359
NANOMI BV	359
NANOMIX, INC.	359
NANOSPEED DIAGNOSTICS, INC.	360
NANOSPHERE, INC.	360
NANOSTRING TECHNOLOGIES INC.	361
NEC CORPORATION	362
NEOGEN CORPORATION	362
NEOGENOMICS LABORATORIES	363
NETBIO, INC.	363
NEXUS DX, INC.	363
NOVARTIS	364
NUCLEA BIOTECHNOLOGIES, INC.	364
ON-Q-ITY	364
OPKO HEALTH, INC.	365
OPTOTRACK, INC.	366
OSMOTEX AG	366
OSTENDUM R&D BV	366
OXFORD GENE TECHNOLOGY	367
PAMGENE INTERNATIONAL BV	367
PATHGEN DX PTE. LTD.	368
PATHOGENETIX, INC.	368
PATHOGENICA	369
PEPPERPRINT GMBH	370
PEPSCAN PRESTO BV	370
PERKINELMER	370
PHALANX BIOTECH GROUP	372
PHILIPS ELECTRONICS NV	372
PLC DIAGNOSTICS, INC.	373
PLEXERA, LLC	373
POSITIVE ID CORPORATION	374
PROTAGEN AG	374
PROTEIN BIOTECHNOLOGIES, INC.	375
PROTEUS DIGITAL HEALTH, INC.	375
PROTNETEOMIX SAS	375
QIAGEN	376
QIAGEN MARSEILLE	376
Q-LINEA AB	377
QUANTERIX CORPORATION	377
QUANTISCIENTIFICS, LLC	378

TOPIC	PAGE NO.
QUANTUM DX	378
QUEST DIAGNOSTICS	379
RAINDANCE TECHNOLOGIES, INC.	380
RANDOX LABORATORIES, LTD.	381
RAYBIOTECH, INC.	381
RETROGENIX LTD.	382
RHEONIX	382
RHEOSENSE, INC.	382
RIDGE DIAGNOSTICS, INC.	383
ROCHE HOLDING AG	383
ROSETTA GENOMICS INC.	384
<i>TABLE 142 ROSETTA'S DIAGNOSTICS TESTS</i>	384
SAMSUNG ELECTRONICS CO. LTD.	385
SANDSTONE DIAGNOSTICS, INC.	385
SAVYON DIAGNOSTICS, LTD.	385
SCIENION AG	386
SEEGENE, INC.	387
<i>TABLE 143 SEEGENE BIOCHIPS COLLABORATIONS</i>	387
SENGENICS INTERNATIONAL PTE LTD	388
SENSIMED AG	389
SENSIVIDA MEDICAL TECHNOLOGIES	389
SENSLAB GMBH	390
SENZAI B.V.	390
SFC FLUIDICS, LLC	390
SHANGHAI BIOCHIP CO., LTD.	391
SHANGHAI HUAGUAN BIOCHIP CO., LTD.	391
SHARP CORPORATION	392
SIALIX, INC.	392
SIGNAL GENETICS, LLC	392
SIGNATURE DIAGNOSTICS AG	393
SILICON BIOSYSTEMS	394
SILOAM BIOSCIENCES, INC.	394
SKYLINE DIAGNOSTICS B.V.	394
SLIPCHIP LLC	395
SOMALOGIC, INC.	395
SONY DADC	396
SOPHION BIOSCIENCE A/S	397
SPARTAN BIOSCIENCES INC.	397
SPHERE FLUIDICS LIMITED	398
SPHERE MEDICAL LTD.	398
SPINCHIP DIAGNOSTICS AS	399
SPINOMIX	399
SQI DIAGNOSTICS, INC.	399
SUPERIOR NANOBIOSYSTEMS	400
SURMODICS, INC.	400
SURNETICS	400
T2 BIOSYSTEMS	401

TOPIC	PAGE NO.
TEARLAB CORPORATION	401
TECAN GROUP LTD.	402
THERMO FISHER SCIENTIFIC, INC.	402
THINXXS MICROTECHNOLOGY AG	403
TIANJIN BIOCHIP CORPORATION	404
TIRF LABS, INC.	404
TRANSGENOMIC, INC.	404
TRANSLUME, INC.	405
TRIANJA TECHNOLOGIES, INC.	405
TRINEAN NV	406
TRINITY BIOTECH PLC	406
TROVAGENE, INC.	407
US BIOMAX, INC.	407
VERACYTE INC.	408
VEREDUS LABORATORIES PTE, LTD.	408
WAFERGEN BIOSYSTEMS, INC.	409
WASATCH MICROFLUIDICS	409
WAVE 80 BIOSCIENCES	410
WUXI BUOSHENG BIO-ENGINEERING CO., LTD.	410
XAGENIC, INC.	411
XONA MICROFLUIDICS LLC	411
YMC CO., LTD.	411
ZELLKRAFTWERK GMBH	412
ZYOMYX, INC.	412
ZYOXEL LTD.	413

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL VALUE OF BIOCHIP PRODUCTS BY END USE, THROUGH 2018 (\$ MILLIONS)	7
TABLE 1 BIOLOGY DOWNSIZING REVOLUTION	11
TABLE 2 COMPARISON OF THE TWO MAJOR BIOCHIP TYPES	12
TABLE 3 BIOCHIP NOMENCLATURE	13
TABLE 4 SCOPE OF REPORT	14
TABLE 5 GLOBAL VALUE OF BIOCHIP PRODUCTS BY BIOCHIP TYPE, THROUGH 2018 (\$ MILLIONS)	15
TABLE 6 GLOBAL VALUE OF BIOCHIPS BY ANALYSIS FUNCTION, THROUGH 2018 (\$ MILLIONS)	16
TABLE 7 BIOCHIPS KEY MARKET GROWTH DRIVING FORCES	17
TABLE 8 COMPARISON OF BIOCHIPS INDUSTRIES	18
TABLE 9 THE NANOSCALE WORLD	21
TABLE 10 MICROARRAY TYPES	22
TABLE 11 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES	22
TABLE 12 MICROARRAY GENOME CONTENT	25
TABLE 13 DNA MICROARRAY PLATFORM FEATURES	26
TABLE 14 DNA MICROARRAY APPLICATIONS	27
TABLE 15 GENETIC ANALYSIS TECHNOLOGIES COMPARISON	28
TABLE 16 SNP MEASUREMENT PLATFORMS	31
TABLE 17 COMPARISON OF CHROMOSOMAL CHANGE DETECTION TECHNOLOGIES	34
TABLE 18 WORKFLOW FOR A MICRO-RNA EXPERIMENT	36
TABLE 19 BEAD-BASED ARRAYS VERSUS PLANAR MICROARRAYS	37
TABLE 20 PROTEIN MICROARRAY PLATFORMS	40
TABLE 21 PROTEIN MICROARRAYS AS RESEARCH TOOLS	41
TABLE 22 PROTEIN MICROARRAY PRODUCT TYPES	42
TABLE 23 PROTEIN MICROARRAY TECHNICAL CHALLENGES	44
TABLE 24 EMERGING MICROARRAY TECHNOLOGIES	47
TABLE 25 LOAC PRODUCT LIFE CYCLE STAGE	51
TABLE 26 BIOCHIPS SUBSTRATE MATERIALS	52
TABLE 27 LOAC TYPES	53
TABLE 28 WORKFLOW COMPARISON OF SELECTED NEXT-GENERATION DNA SEQUENCING PLATFORMS	58
TABLE 29 BIOCHIP CONTENT IN NEXT-GENERATION SEQUENCING MACHINES	58
TABLE 30 LOAC MARKET SEGMENTS	60
TABLE 31 MICROFLUIDIC SYSTEMS ADVANTAGES FOR BIOCHEMICAL ANALYSIS	61
TABLE 32 LOAC TECHNOLOGY CHALLENGES	62
TABLE 33 BIOCHIP KEY LIFE-SCIENCES MARKET SEGMENTS	65
TABLE 34 BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT	68
TABLE 35 KEY NEEDS IN DRUG DISCOVERY AND DEVELOPMENT	74
TABLE 36 DIAGNOSTICS PARADIGM SHIFT	79
TABLE 37 REQUIREMENTS FOR AN EPIGENETICS BISULFITE DIAGNOSTIC ASSAY	80
TABLE 38 BIOMARKERS USED IN BIOCHIP-BASED DIAGNOSTICS	81
TABLE 39 RATE OF ADOPTION OF DNA MICROARRAY DIAGNOSTICS TESTS	83
TABLE 40 COMPARISON OF DNA-BASED MDX PLATFORMS	86
TABLE 41 FACTORS AFFECTING PENETRATION OF NEXT-GENERATION FORMATS INTO THE MDX MARKET	87

TABLE HEADING	PAGE NO.
TABLE 42 ESTIMATED U.S. INCIDENCE FOR SELECTED CANCERS, 2012	92
TABLE 43 STATUS OF ADVANCED BLADDER CANCER DIAGNOSTICS	93
TABLE 44 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT DECISIONS IN THE U.S. BY CANCER CLASSIFICATION	96
TABLE 45 BREAST CANCER MDX TECHNOLOGY PLATFORMS	97
TABLE 46 STATUS OF ADVANCED BREAST CANCER DIAGNOSTICS	98
TABLE 47 STATUS OF ADVANCED HPV DIAGNOSTICS	104
TABLE 48 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL CANCER	107
TABLE 49 STATUS OF ADVANCED COLORECTAL CANCER DIAGNOSTICS	108
TABLE 50 CANCER UNKNOWN PRIMARY INDUSTRY	111
TABLE 51 STATUS OF ADVANCED KIDNEY CANCER DIAGNOSTICS	113
TABLE 52 STATUS OF ADVANCED LEUKEMIA DIAGNOSTICS	114
TABLE 53 STATUS OF LIVER CANCER NEXT-GENERATION DX TESTS	117
TABLE 54 STATUS OF ADVANCED LYMPHOMA CANCER DIAGNOSTICS	118
TABLE 55 FIVE-YEAR SURVIVAL RATES FOR NON SMALL CELL LUNG CANCER (%)	119
TABLE 56 STATUS OF ADVANCED LUNG CANCER DIAGNOSTICS	120
TABLE 57 STATUS OF ADVANCED MELANOMA DIAGNOSTICS	125
TABLE 58 EARLY SCREENING OVARIAN CANCER TESTS	126
TABLE 59 STATUS OF OVARIAN CANCER NEXT-GENERATION DIAGNOSTICS TESTS	127
TABLE 60 STATUS OF ADVANCED PANCREATIC CANCER DIAGNOSTICS	129
TABLE 61 STATUS OF ADVANCED PROSTATE CANCER DIAGNOSTICS	132
TABLE 62 STATUS OF ADVANCED THYROID CANCER DIAGNOSTICS	135
TABLE 63 NEXT-GENERATION DX TEST SUMMARY BY INDICATION AND BY TECHNOLOGY	136
TABLE 64 IMPORTANCE OF CYP GENES IN DRUG METABOLISM	138
TABLE 65 STATUS OF ADVANCED WARFARIN CYP PHARMACOGENETIC DIAGNOSTICS	139
TABLE 66 STATUS OF MRSA AND C. DIFFICILE ADVANCED DIAGNOSTICS	142
TABLE 67 STATUS OF INFLUENZA ADVANCED DIAGNOSTICS	144
TABLE 68 STATUS OF CT/NG ADVANCED DIAGNOSTICS	146
TABLE 69 ALZHEIMER'S DISEASE DIAGNOSTICS APPROACHES	148
TABLE 70 STATUS OF ALZHEIMER'S DISEASE ADVANCED DIAGNOSTICS TESTS	148
TABLE 71 BNP MOLECULAR DIAGNOSTICS TESTS FOR CONGESTIVE HEART FAILURE	151
TABLE 72 CYSTIC FIBROSIS ADVANCED DIAGNOSTICS TESTS	153
TABLE 73 NEXT-GENERATION SEQUENCING-BASED PRENATAL DIAGNOSTICS INDUSTRY	155
TABLE 74 HLA TESTING MARKET	157
TABLE 75 ACQUISITIONS IN THE BIOCHIPS INDUSTRY, 2012-2013	161
TABLE 76 MICROARRAY INDUSTRY STRATEGIC ALLIANCES, 2012-2013	165
TABLE 77 LOC/NGS INDUSTRY STRATEGIC ALLIANCES, 2012-2013	169
TABLE 78 LOAC COMPETITOR LANDSCAPE	178
TABLE 79 LEADING LOAC INSTRUMENT MANUFACTURERS	180
TABLE 80 FORENSIC APPLICATIONS FOR LOAC-BASED DNA ANALYZERS	181
TABLE 81 LOAC DIAGNOSTICS INDUSTRY	182
TABLE 82 ION CHANNEL SCREENING INDUSTRY	183
TABLE 83 DIGITAL PCR INDUSTRY	184
TABLE 84 LOC UNIVERSITY SPIN-OFFS	185
TABLE 85 LEADING LIFE SCIENCE COMPANIES ACQUISITIONS IN LOAC	186

TABLE HEADING	PAGE NO.
TABLE 86 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES: COMMERCIAL PHASE	187
TABLE 87 SUSPENSION BEAD/GEL-BASED MICROARRAY INDUSTRY	188
TABLE 88 LABEL-FREE DETECTION INDUSTRY	189
TABLE 89 NANOARRAY INDUSTRY	191
TABLE 90 KEY PEPTIDE MICROARRAY COMPANIES	192
TABLE 91 KEY ANTIBODY MICROARRAY COMPANIES	193
TABLE 92 MARKET SHARE FOR KEY ANTIBODY REAGENTS COMPANIES	194
TABLE 93 MULTIPLEX PROTEIN IN VITRO DIAGNOSTICS COMPANIES	195
TABLE 94 CTC BIOCHIPS INDUSTRY	198
TABLE 95 NORTH AMERICAN TEST COSTS AND PRICES (\$)	200
TABLE 96 NEXT-GENERATION SEQUENCING-BASED, NONINVASIVE PRENATAL DIAGNOSTIC MARKET SHARE BY TEST REVENUE, 2013 (%)	201
TABLE 97 NONINVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE COMPETITORS	202
TABLE 98 POC CD4 INDUSTRY	203
TABLE 99 BIOCHIPS-BASED COMPANIES IN AGRICULTURAL INDUSTRY	204
TABLE 100 CHINA BIOCHIP INDUSTRY	206
TABLE 101 BIOCHIPS KEY MARKET GROWTH DRIVING FORCES	210
TABLE 102 GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, THROUGH 2018 (\$ MILLIONS)	211
TABLE 103 GLOBAL VALUE OF BIOCHIP MARKET BY END-USE INDUSTRY, THROUGH 2018 (\$ MILLIONS)	212
TABLE 104 BIOCHIPS SUBSTRATE MATERIALS	213
TABLE 105 GLOBAL VALUE OF BIOCHIP MARKET BY SUBSTRATE MATERIAL, THROUGH 2018 (\$ MILLIONS)	213
TABLE 106 GLOBAL VALUE OF DNA MICROARRAYS BY END USE, THROUGH 2018 (\$ MILLIONS)	214
TABLE 107 GLOBAL VALUE OF DNA MICROARRAYS BY ANALYSIS TYPE, THROUGH 2018 (\$ MILLIONS)	216
TABLE 108 GLOBAL VALUE OF DNA MICROARRAYS BY SUBSTRATE MATERIAL, THROUGH 2018 (\$ MILLIONS)	219
TABLE 109 COMPETITIVE PLATFORMS BY MULTIPLEXING DENSITY	220
TABLE 110 GLOBAL VALUE OF PROTEIN MICROARRAYS BY END USE, THROUGH 2018 (\$ MILLIONS)	221
TABLE 111 GLOBAL VALUE OF PROTEOMIC MICROARRAYS BY SUBSTRATE MATERIAL, THROUGH 2018 (\$ MILLIONS)	223
TABLE 112 COATED MICROARRAY SLIDE MARKET PRINCIPAL COMPETITORS	223
TABLE 113 GLOBAL VALUE OF PROTEOMIC ARRAYS BY ARRAY TYPE, THROUGH 2018 (\$ MILLIONS)	224
TABLE 114 GLOBAL VALUE OF EMERGING ARRAYS, BY ARRAY TYPE, THROUGH 2018 (\$ MILLIONS)	225
TABLE 115 GLOBAL VALUE OF EMERGING ARRAYS BY END USE, THROUGH 2018 (\$ MILLIONS)	226
TABLE 116 GLOBAL VALUE OF EMERGING ARRAYS BY SUBSTRATE MATERIAL, THROUGH 2018 (\$ MILLIONS)	227
TABLE 117 GLOBAL VALUE OF GENOMICS LAB-ON-A-CHIP BY END-USER INDUSTRY, THROUGH 2018 (\$ MILLIONS)	228
TABLE 118 GLOBAL VALUE OF GENOMICS LOAC BY SUBSTRATE MATERIAL, THROUGH 2018 (\$ MILLIONS)	229
TABLE 119 GLOBAL VALUE OF PROTEOMIC LAB-ON-A-CHIP BY END-USER INDUSTRY, THROUGH 2018 (\$ MILLIONS)	230

TABLE HEADING	PAGE NO.
TABLE 120 GLOBAL VALUE OF PROTEOMICS LOAC BY SUBSTRATE MATERIAL, THROUGH 2018	232
TABLE 121 GLOBAL VALUE OF NGS MARKET BY END-USER INDUSTRY, THROUGH 2018 (\$ MILLIONS)	233
TABLE 122 GLOBAL VALUE OF NGS BY SUBSTRATE MATERIAL, THROUGH 2018 (\$ MILLIONS)	234
TABLE 123 GLOBAL VALUE OF NGS BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)	235
TABLE 124 GLOBAL VALUE OF DIAGNOSTICS MARKET, BY BIOCHIP TYPE, THROUGH 2018 (\$ MILLIONS)	238
TABLE 125 ADOPTION RATE FOR DNA MICROARRAYS IN DIAGNOSTICS	240
TABLE 126 GLOBAL VALUE OF DIAGNOSTICS MARKET, BY INDICATION, THROUGH 2018 (\$ MILLIONS)	241
TABLE 127 GLOBAL VALUE OF DIAGNOSTICS MARKET BY SUBSTRATE MATERIAL, THROUGH 2018 (\$ MILLIONS)	246
TABLE 128 GLOBAL VALUE OF CANCER DIAGNOSTICS MARKET BY BIOCHIP TYPE, THROUGH 2018 (\$ MILLIONS)	247
TABLE 129 GLOBAL VALUE OF CANCER DIAGNOSTICS MARKET BY INDICATION, THROUGH 2018 (\$ MILLIONS)	248
TABLE 130 2013 STATUS OF PROTEOMICS-BASED DIAGNOSTICS FOR CANCER APPLICATIONS	249
TABLE 131 GLOBAL VALUE OF BIOCHIPS MARKET BY GEOGRAPHY, THROUGH 2018 (\$ MILLIONS)	251
TABLE 132 GLOBAL VALUE OF MICROARRAY MARKET BY GEOGRAPHY, THROUGH 2018 (\$ MILLIONS)	253
TABLE 133 GLOBAL VALUE OF LOAC MARKET BY GEOGRAPHY, THROUGH 2018 (\$ MILLIONS)	254
TABLE 134 GLOBAL VALUE OF NGS MARKET BY GEOGRAPHY, THROUGH 2018 (\$ MILLIONS)	255
TABLE 135 DNA MICROARRAY PATENTS BY REGION, 2002-2012	258
TABLE 136 MICROARRAY-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012	259
TABLE 137 LOAC-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012	260
TABLE 138 CLINICAL NEXT-GENERATION SEQUENCING PATENTS, 2002-2012	261
TABLE 139 CLINICAL NEXT-GENERATION SEQUENCING PATENTS BY INDICATION, 2002-2012	261
TABLE 140 AGENDIA MICROARRAY-BASED DIAGNOSTICS PIPELINE	271
TABLE 141 AKONNI BIOCHIP GRANTS	274
TABLE 142 ROSETTA'S DIAGNOSTICS TESTS	384
TABLE 143 SEEGENE BIOCHIPS COLLABORATIONS	387

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL VALUE OF BIOCHIP PRODUCTS BY END USE, 2012-2018 (\$ MILLIONS)	7
FIGURE 1 MICROARRAY FEATURE DENSITY	24
FIGURE 2 MICROARRAY RESOLUTION	24
FIGURE 3 RELATIVE NUMBER OF DISEASE-CAUSING ALLELES AT MAF5 AND MAF1	29
FIGURE 4 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS	32
FIGURE 5 IMPORTANCE OF PROTEINS	38
FIGURE 6 PROTEIN ANALYSIS APPROACHES CONTRASTED	39
FIGURE 7 DRUG DISCOVERY AND DEVELOPMENT TIMESCALE	67
FIGURE 8 VALIDATION GAP FOR FUTURE DRUG TARGETS	76
FIGURE 9 SENSITIVITY AND SPECIFICITY	90
FIGURE 10 ENTRIES TO MIRNA DATABASE, 2002-2013 (NO. OF MIRNAS)	218